Literature DB >> 34278782

Synergistic Immunostimulation through the Dual Activation of Toll-like Receptor 3/9 with Spherical Nucleic Acids.

Ziyin N Huang, Cassandra E Callmann, Lisa E Cole, Shuya Wang, Chad A Mirkin.   

Abstract

Toll-like receptors (TLRs) are a family of proteins that modulate the innate immune system and control the initiation of downstream immune responses. Spherical nucleic acids (SNAs) designed to stimulate single members of the TLR family (e.g., TLR7 or TLR9) have shown utility in cancer immunotherapy. We hypothesized that SNAs synthesized with multiple TLR agonists would enable the simultaneous activation of multiple TLR pathways for maximally synergistic immune activation. Here, we describe the synthesis of SNAs that incorporate both a TLR3 agonist (polyinosinic:polycytidylic acid, poly(I:C)) and TLR9 agonist (CpG oligonucleotide) on the same liposomal scaffold. In this design, CpG comprises the SNA oligonucleotide shell, and poly(I:C) is encapsulated in the liposome core. These dual-TLR activating SNAs efficiently codeliver high quantities of both agonists to the same target cell, yielding enhanced immunostimulation in various murine and human antigen-presenting cells (APCs). Moreover, codelivery of TLR agonists using the SNA both synchronizes and prolongs the duration of costimulatory molecule and major histocompatibility complex class II expression in APCs, which has been shown to be important for efficient downstream immune responses. Taken together, this SNA design provides a strategy for potently activating immune cells and increasing the efficiency of their activation, which likely will inform the preparation of nanomaterials for highly potent immunotherapies.

Entities:  

Keywords:  DNA nanotechnology; biotechnology; immunotherapy; spherical nucleic acids; toll-like receptors

Year:  2021        PMID: 34278782      PMCID: PMC8766625          DOI: 10.1021/acsnano.1c03093

Source DB:  PubMed          Journal:  ACS Nano        ISSN: 1936-0851            Impact factor:   15.881


  56 in total

1.  The TLR3 signaling complex forms by cooperative receptor dimerization.

Authors:  Joshua N Leonard; Rodolfo Ghirlando; Janine Askins; Jessica K Bell; David H Margulies; David R Davies; David M Segal
Journal:  Proc Natl Acad Sci U S A       Date:  2008-01-02       Impact factor: 11.205

Review 2.  Toll-like receptors and cancer.

Authors:  Seth Rakoff-Nahoum; Ruslan Medzhitov
Journal:  Nat Rev Cancer       Date:  2008-12-04       Impact factor: 60.716

3.  Using 3 TLR ligands as a combination adjuvant induces qualitative changes in T cell responses needed for antiviral protection in mice.

Authors:  Qing Zhu; Colt Egelston; Susan Gagnon; Yongjun Sui; Igor M Belyakov; Dennis M Klinman; Jay A Berzofsky
Journal:  J Clin Invest       Date:  2010-01-25       Impact factor: 14.808

4.  Toll-like receptor ligands synergize through distinct dendritic cell pathways to induce T cell responses: implications for vaccines.

Authors:  Qing Zhu; Colt Egelston; Aravindhan Vivekanandhan; Satoshi Uematsu; Shizuo Akira; Dennis M Klinman; Igor M Belyakov; Jay A Berzofsky
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-09       Impact factor: 11.205

5.  A scalable, extrusion-free method for efficient liposomal encapsulation of plasmid DNA.

Authors:  Lloyd B Jeffs; Lorne R Palmer; Ellen G Ambegia; Cory Giesbrecht; Shannon Ewanick; Ian MacLachlan
Journal:  Pharm Res       Date:  2005-03       Impact factor: 4.200

6.  The physiological regulation of toll-like receptor expression and function in humans.

Authors:  Graeme I Lancaster; Qamar Khan; Pam Drysdale; Fiona Wallace; Asker E Jeukendrup; Mark T Drayson; Michael Gleeson
Journal:  J Physiol       Date:  2005-01-20       Impact factor: 5.182

7.  Exploration of the nanomedicine-design space with high-throughput screening and machine learning.

Authors:  Gokay Yamankurt; Eric J Berns; Albert Xue; Andrew Lee; Neda Bagheri; Milan Mrksich; Chad A Mirkin
Journal:  Nat Biomed Eng       Date:  2019-02-18       Impact factor: 25.671

8.  Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3.

Authors:  L Alexopoulou; A C Holt; R Medzhitov; R A Flavell
Journal:  Nature       Date:  2001-10-18       Impact factor: 49.962

9.  Critical role of TLR7 in the acceleration of systemic lupus erythematosus in TLR9-deficient mice.

Authors:  Marie-Laure Santiago-Raber; Isabelle Dunand-Sauthier; Tianfu Wu; Quan-Zhen Li; Satoshi Uematsu; Shizuo Akira; Walter Reith; Chandra Mohan; Brian L Kotzin; Shozo Izui
Journal:  J Autoimmun       Date:  2009-11-26       Impact factor: 7.094

10.  Impaired cytokine response in myeloid dendritic cells in chronic hepatitis C virus infection regardless of enhanced expression of Toll-like receptors and retinoic acid inducible gene-I.

Authors:  Masanori Miyazaki; Tatsuya Kanto; Michiyo Inoue; Ichiyo Itose; Hideki Miyatake; Mitsuru Sakakibara; Takayuki Yakushijin; Naruyasu Kakita; Naoki Hiramatsu; Tetsuo Takehara; Akinori Kasahara; Norio Hayashi
Journal:  J Med Virol       Date:  2008-06       Impact factor: 2.327

View more
  4 in total

Review 1.  Rational Vaccinology: Harnessing Nanoscale Chemical Design for Cancer Immunotherapy.

Authors:  Ziyin Huang; Cassandra E Callmann; Shuya Wang; Matthew K Vasher; Michael Evangelopoulos; Sarah Hurst Petrosko; Chad A Mirkin
Journal:  ACS Cent Sci       Date:  2022-05-20       Impact factor: 18.728

Review 2.  Spherical Nucleic Acids as Precision Therapeutics for the Treatment of Cancer-From Bench to Bedside.

Authors:  Akanksha S Mahajan; Alexander H Stegh
Journal:  Cancers (Basel)       Date:  2022-03-23       Impact factor: 6.639

Review 3.  Nucleic acid strategies for infectious disease treatments: The nanoparticle-based oral delivery route.

Authors:  Fengqian Chen; Qi Liu; Yang Xiong; Li Xu
Journal:  Front Pharmacol       Date:  2022-08-29       Impact factor: 5.988

4.  Intratumoral immunotherapy using a TLR2/3 agonist, L-pampo, induces robust antitumor immune responses and enhances immune checkpoint blockade.

Authors:  Won Suk Lee; Dong Sung Kim; Jeong Hun Kim; Yoonki Heo; Hannah Yang; Eun-Jin Go; Jin Hyoung Kim; Seung Joon Lee; Byung Cheol Ahn; Jung Sun Yum; Hong Jae Chon; Chan Kim
Journal:  J Immunother Cancer       Date:  2022-06       Impact factor: 12.469

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.